Matching articles for "tucatinib"
In Brief: A Second Indication for Tucatinib (Tukysa) (online only)
The Medical Letter on Drugs and Therapeutics • February 20, 2023; (Issue 1670)
The oral kinase inhibitor tucatinib (Tukysa – Seagen)
has received accelerated approval from the FDA for
use in combination with trastuzumab (Herceptin)
for treatment of adults with RAS wild-type...
The oral kinase inhibitor tucatinib (Tukysa – Seagen)
has received accelerated approval from the FDA for
use in combination with trastuzumab (Herceptin)
for treatment of adults with RAS wild-type human
epidermal growth factor receptor 2 (HER2)-positive
unresectable or metastatic colorectal cancer
that has progressed following treatment with
fluoropyrimidine-, oxaliplatin-, and irinotecan-based
chemotherapy regimens. Tucatinib was approved in
2020 for use in combination with trastuzumab and
capecitabine (Xeloda, and generics) for treatment
of adults with advanced unresectable or metastatic
HER2-positive breast cancer, including those with
brain metastases, who received at least one prior
anti-HER2-based regimen for metastatic disease.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • November 16, 2020; (Issue 1611)
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.